DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.
| Revenue (TTM) | $13.84B |
| Gross Profit (TTM) | $4.49B |
| EBITDA | $2.79B |
| Operating Margin | 13.90% |
| Return on Equity | 81.00% |
| Return on Assets | 7.50% |
| Revenue/Share (TTM) | $194.22 |
| Book Value | $-11.41 |
| Price-to-Book | 21.63 |
| Price-to-Sales (TTM) | 1.11 |
| EV/Revenue | 2.004 |
| EV/EBITDA | 10.24 |
| Quarterly Earnings Growth (YoY) | 43.50% |
| Quarterly Revenue Growth (YoY) | 6.00% |
| Shares Outstanding | $64.19M |
| Float | $34.17M |
| % Insiders | 46.90% |
| % Institutions | 52.97% |
Volatility is currently expanding
DVA's IKC momentum, higher 2026 guidance and technology investments support growth, while reimbursement and payer-mix risks cloud the outlook.
DENVER, July 21, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 4, 2026, at 5:00 p.m. Eastern Time.
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $234.01, denoting a +1.04% move from the preceding trading day.
DaVita Inc. has more than doubled in share price within six months, driven by a strong Q1 '26 beat and a favorable court ruling. DVA fundamentals and long-term prospects remain largely unchanged, with 2026E AEPS recovery now expected at 30%+ and 10–16% annualized growth through 2028. I sold over 95% of my DVA position as the valuation exceeded $210/share, far above my fair value target of $130/share.
DaVita HealthCare (DVA) reached $230.72 at the closing of the latest trading day, reflecting a -1.53% change compared to its last close.
ADM, CASY, DVA, CVS and BEN top a list of five non-AI S&P 500 stocks that surged more than 30% in 1H 2026 and still show momentum for 2H.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 2, 2026.
DVA is advancing kidney care through IKC expansion, CMS CKCC progress and AI-driven dialysis scheduling improvements.
DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 30, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DVA and any ticker you trade — then tracks every position and per-strategy win rate.
